Outlook Therapeutics (NASDAQ:OTLK) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Outlook Therapeutics (NASDAQ:OTLK) announced its earnings results on Friday. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.06, Zacks reports.

Outlook Therapeutics Stock Performance

NASDAQ:OTLK traded up $0.29 during trading hours on Friday, reaching $1.99. The stock had a trading volume of 929,598 shares, compared to its average volume of 696,743. The stock has a market cap of $47.07 million, a P/E ratio of -0.19 and a beta of 0.47. The stock has a 50 day simple moving average of $3.88 and a 200 day simple moving average of $5.94. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85.

Analyst Upgrades and Downgrades

OTLK has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a research note on Friday, November 29th. BTIG Research decreased their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 29th. Ascendiant Capital Markets dropped their price target on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. Finally, Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Outlook Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $42.34.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.